Amnesia
Sheryl R. Haut
<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program and Chief of Service, Neurology at Montefiore Einstein. She is the previous Chair of the North American Commission of the International League Against Epilepsy. Her research interests include: the temporal distribution of seizures, with emphasis on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is currently conducting electronic diary studies of seizure prediction and was the Principal Investigator of the first randomized controlled trial of stress management for refractory epilepsy using smartphone diaries. Dr. Haut has a Masters in Clinical Research Methods, and completed a K23 career development award from the NIH. She maintains an active adult epilepsy practice at Montefiore Medical Center, Moses Division.</p>
Dr. Haut focuses on the special needs of epilepsy patients, such as pregnancy, stress, driving, work-related issues and issues in the elderly.
Dr. Haut's research is focused on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy.
<ol>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><!-- [if !supportLists]--><span style="mso-bidi-font-size: 12.0pt; border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in;">Correa DJ, Labovitz DL, Milstein MJ, Monderer R, Haut SR. <strong><span style="font-weight: normal; mso-bidi-font-weight: bold;">Folding a neuroscience </span></strong></span><strong style="text-indent: -0.25in;"><span style="font-weight: normal; mso-bidi-font-weight: bold;">center into streamlined Covid-19 response teams: Lessons in origami. Neurology 2020, in press.</span></strong></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><span class="author" style="text-indent: -0.25in;"><span lang="EN">Galanopoulou, AS</span></span><span lang="EN" style="text-indent: -0.25in;">, <span class="author">Ferastraoaru, V</span>, <span class="author">Correa, DJ</span>, </span><span lang="EN" style="text-indent: -0.25in;">Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler M, Ballaban-Gil K, Haut SR, Moshé SL, Boro A. </span><span lang="EN" style="text-indent: -0.25in;"> <span class="articletitle">EEG findings in acutely ill patients investigated for SARS</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">CoV-2/COVID</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">19: A small case series preliminary report</span></span><span lang="EN" style="text-indent: -0.25in;">. Epilepsia Open. <span class="pubyear">2020</span>; <span class="vol">5</span>: <span class="pagefirst">314</span>– <span class="pagelast">324</span>. </span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Chiang S, </span></span></a><a name="baut0015"></a>Haut SR. <a name="baut0020"></a>Ferastaoaru V, <a name="baut0025"></a>Rao VR, <a name="baut0030"></a> M, <a name="baut0035"></a>Theodore WH, <a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Moss</span></span></a><a name="baut0040"></a> R, Goldenholz DM. <span class="title-text">Individualizing the definition of seizure clusters based on temporal clustering analysis. Epilepsy Res 2020;163:1-10.</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><strong style="text-indent: -0.25in;"><span style="font-weight: normal;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span></strong><strong style="text-indent: -0.25in;"><span style="border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in; font-weight: normal; mso-bidi-font-weight: bold;">Privitera M, Haut SR, Lipton RB, McGinley J, Cornes S. Seizure Self-prediction in a Randomized Controlled Trial of Stress Management. Neurology 2019;93(22):e2021-e2031</span></strong><span style="text-indent: -0.25in; color: windowtext;">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in; color: windowtext;">Ferastraoaru V, Goldenholz DM, Chiang S, Moss R, Theodore WH, Haut SR. Characteristics of large patient-reported outcomes: Where can one million seizures get us? Epilepsia Open. 2018 Jul 4;3(3):364-373 </span></p>
</li>
<li>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span><span lang="EN" style="text-indent: -0.25in;">Goldenholz DM, Goldenholz SR, Moss R, French J, Lowenstein D, Kuzniecky R, Haut S, Cristofaro S, Detyniecki K, Hixson J, Karoly P, Cook M, Strashny A, Theodore WH. Is seizure frequency variance a predictable quantity? Ann Clin Transl Neurol. 2018 Jan 9;5(2):201-207</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span><span style="text-indent: -0.25in;">Haut SR, Lipton RB, Cornes S, Dwivedi AK, Wasson R, Cotton S, Strawn J, Privitera M. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial. </span><span class="jrnl" style="text-indent: -0.25in;">Neurology</span><span style="text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">. 2018 Mar 13;90(11)</span></p>
<p style="margin-left: .25in; text-indent: -.25in; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in;"> </p>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </p>
</li>
<li>Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian E, Zuberi SM. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017 Apr;58(4):531-542</li>
<li>Patel P, Ferastaoaru V, Gold D, Lipnick A, Jehle R, Haut SR. Clinical characterization of the pre-ictal state in the pediatric population: A caretaker’s perspective. Epilepsy Behav. 2017 Apr 18;70(Pt A):193-197</li>
<li>Robbins MS, Haut SR, Lipton RB, Milstein MJ, Ocava LC, Ballaban-Gil K, Moshé SL, Mehler MF. A dedicated scholarly research program in an adult and pediatric neurology residency program. Neurology. 2017 Apr 4;88(14):1366-1370</li>
<li>Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in Seizure emergencies: A systematic review. Epilepsy Behav. 2016 Oct;63:109-117.</li>
<li>Ferastraoaru V, Schulze-Bonhage A, Lipton RB, Dümpelmann M, Legatt AD, Blumberg J, Haut SR. Termination of seizure clusters is related to the duration of focal seizures. Epilepsia 2016 Mar 31.</li>
<li>Pillai J, Haut SR, Masur D. Orbitofrontal cortex dysfunction in Psychogenic Non-Epileptic Seizures. A proposal for a two-factor model. Med Hypotheses. 2015 Apr;84(4):363-9</li>
<li>Haut SR. Seizure Clusters: Characteristics and Treatment. Curr Opin Neurol. 2015 Apr;28(2):143-50</li>
<li>Lipton RB,BuseDC, Hall CB, Tennen H, DeFreitas TA, Borkowski TM, Haut SR. Reduction in Perceived Stress as a Migraine Trigger: Testing the “Let-down Headache” Hypothesis. Neurology 2014; Apr 22;82(16):1395-401</li>
<li>Privitera M, Walters M, Lee I, Polak E, Fleck A, Schwieterman D, Haut SR. Characteristics of People with Stress Precipitated Seizures. Epilepsy Behav 2014 Oct;41:74-77</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Modeling seizure self-prediction: An e-diary study. Epilepsia 2013; Nov;54(11):1960-7.</li>
<li>Haut SR. Predicting seizures: Are we there yet? Epilepsy Currents 2013 Nov;13(6):276-8.</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Clinical features of the pre-ictal state: Mood changes and premonitory symptoms. Epilepsy and Behavior 2012, 23:415-421.</li>
<li>Pillai J, Haut SR. Patients with epilepsy and psychogenic non-epileptic seizures: An inpatient video-EEG monitoring study. Seizure. 2012, 21(1):24-7.</li>
<li>Schulze-BonhageA, Haut SR. Premonitory features and seizure self-prediction: Artifact or real? Epilepsy Res 2011, 97(3);231-235.</li>
<li>Haut SR, Lipton RBL. Predicting Seizures: A Behavioral Approach. Neurol Clinics 2009, 27(4);925-940.</li>
<li>Haut SR. Psychiatric History and Temporal Lobectomy Outcome: Looking to the Past to Predict the Future. Epilepsy Currents 2009, 9(5):1-3</li>
<li>Haut SR, Katz M, Masur J, Lipton RBL. Seizures in the Elderly: Impact on Mental Status, Mood and Sleep. Epilepsy and Behavior 2009;14(3):540-544.</li>
<li>Hall CB, Lipton RB, Tennen H, Haut SR. Early Follow-up Data From Seizure Diaries Can Be Used To Predict Subsequent Seizures in Same Cohort By Borrowing Strength Across Participants. Epilepsy and Behavior 2009;14(3);472-475.</li>
<li>Bower CM, Hays RD, Devinsky O, Spencer SS, Sperling MR, Haut S, Vassar S, Vickrey BG. Expectations Prior to Epilepsy Surgery: An Exploratory Comparison of Men and Women. Seizure 2009;18(3):228-231</li>
<li>Brody BD and Haut SR. Ending the Doctor-Patient Relationship in Neurology Practice. The Neurologist 2009;15(5): 277-81.</li>
<li>Haut SR, Hall CD, Masur J, Lipton RB. Seizure Occurrence: Precipitants and Prediction. Neurology 2007;69 1905-1910.</li>
<li>Lado F, Spiegel R, Masur J, Boro A, Haut SR. Value of routine screening for bone demineralization in an urban population of patients with epilepsy. Epil Res 2007; 78(2-3);155-160</li>
<li>Chin PS, Berg AT, Spencer SS, Sperling MR, Haut S et al. Employment Outcomes Following Resective Epilepsy Surgery. Epilepsia 2007;Dec;48(12):2253-7.8.<span style="font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-size: 7.0pt; line-height: normal; font-variant: normal;"> </span></li>
<li>Haut SR, Hall CD, LeValley A, Lipton RB. Can patients with epilepsy predict their seizures? Neurology, 2007; 68:262-266.</li>
<li>Spencer SS, Berg AT, Vickrey BG, Sperling MR, Bazil CW, Haut S, Langfitt JT, Walczak TS, Devinsky O; Multicenter Study of Epilepsy Surgery. Health-related quality of life over time since resective epilepsy surgery. Ann Neurol. 2007 Oct;62(4):327-34</li>
<li>Haut SR, Bigal M, Lipton RB. Chronic Disorders With Episodic Manifestations: Focus on Epilepsy and Migraine. Lancet Neurology 2006;5:148-157. </li>
</ol>
<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program at Montefiore. She has extensive experience treating all forms of epilepsy in young and older adults, and in tailoring treatments to the individual. She focuses on special needs such as pregnancy, stress, driving, work related issues, and issues in the elderly.</p> <p>Dr. Haut has an extensive research background, including a Masters of Clinical Research with Distinction from Albert Einstein College of Medicine. Her research interests focus on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is one of the first investigators to run a clinical trial of stress management for epilepsy, using smartphone diaries.</p> <p>Dr. Haut is the current Chair of the North American Commission of the International League Against Epilepsy, and is active nationally in the American Epilepsy Society, and the American Academy of Neurology, serving on committees of both organizations. She has authored more than 50 papers/book chapters on epilepsy, and has been featured in Top Doctors of NY annually since 2009. She maintains an active adult epilepsy practice at the Moses Campus.</p>
Lauren Gluck
<p>After receiving her medical degree from the University at Buffalo School of Medicine, Dr. Gluck completed her medicine internship and neurology residency at Montefiore Medical Center and then her neuroimmunology fellowship at Yale University. She specializes in the diagnosis and treatment of adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis, autoimmune encephalitis, and other inflammatory diseases that affect the central nervous system.</p>
Diagnosis and treatment of adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis, autoimmune encephalitis, and other inflammatory diseases that affect the central nervous system
Clinical outcomes in multiple sclerosis
<p>Lauren Gluck, MD, is the Director of the Montefiore Multiple Sclerosis Center and Assistant Professor at our Albert Einstein College of Medicine. Her clinical focus is on neuroimmunological diseases that affect the brain and spinal cord, including adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis and autoimmune encephalitis.</p><p>In 2010, Dr. Gluck received her Bachelor of Science in biology and community health at Tufts University. She went on to University at Buffalo School of Medicine and Biomedical Sciences, earning her Doctor of Medicine in 2014. She completed her medicine internship and neurology residency at Montefiore Medical Center in 2018, followed by a clinical fellowship in neuroimmunology at Yale New Haven Hospital in 2019.</p><p>Dr. Gluck’s research focus is on the clinical outcomes of multiple sclerosis as well as medical education. She has presented her work at several national and international meetings and has published original communications in many reviewed journals.</p><p>Dr. Gluck has received many recognitions, including the American Academy of Neurology Medical Student Prize for Excellence in Neurology in 2014, and becoming a Consortium of MS Centers Mentorship Forum Scholar in 2018. She is board certified in neurology and is a member of several professional organizations, including the American Medical Association, the American Academy of Neurology and the Federation of Clinical Immunology Societies.</p>
Karen R. Ballaban-Gil
<p>Dr. Karen Ballaban-Gil is Professor of Neurology and Pediatrics, the Director of the Child Neurology Residency Training Program and Director of Outpatient Child Neurology Services at the Albert Einstein College of Medicine. She graduated Magna Cum Laude from Union College and Cum Laude from Albany Medical College, in the 6 year combined B.S- M.D. program. Dr. Ballaban-Gil trained in general pediatrics at The Johns Hopkins Hospital, and trained in child neurology and clinical neurophysiology and epilepsy at the Albert Einstein College of Medicine. She received board certifications in pediatrics, neurology with special competence in child neurology , clinical neurophysiology and in epilepsy.</p>
<p><br />Dr. Ballaban-Gil has a large clinical practice in child neurology, including the evaluation and treatment of children with epilepsy, headaches, sleep disorders, autism and other developmental disabilities. Her research interests include the relationship between epilepsy and language regression in youngsters with Landau-Kleffner Syndrome, autism, and other developmental disorders of higher cognitive functioning. In addition, she runs the Ketogenic Diet program for the management of intractable epilepsy at the Montefiore Medical Center - Comprehensive Epilepsy Center. Her publications include numerous papers on autism, epilepsy related language disorders, and the Ketogenic Diet.</p>
<p> </p>
<p>Karen Ballaban-Gil, MD, is Director, Pediatric Epilepsy Center and Deputy Director, Division of Child Neurology at the Children’s Hospital at Montefiore Einstein, and Professor, Pediatrics and Neurology at our Albert Einstein College of Medicine. Dr. Ballaban-Gil has a large clinical practice in child neurology, including the evaluation and treatment of children with epilepsy, headaches, sleep disorders, autism and other developmental disabilities.</p><p>After receiving her Bachelor of Science at Union College in 1984, Dr. Ballaban-Gil earned her Doctor of Medicine in 1986 at the Albany Medical College. She began her postgraduate training at Johns Hopkins Hospital, completing two years as an intern and assistant resident in pediatrics before coming to Einstein, where she completed a residency in child neurology, followed by a fellowship in epilepsy and electrophysiology in 1991.</p><p>Dr. Ballaban-Gil’s research interests include the relationship between epilepsy and language regression in youngsters with Landau-Kleffner Syndrome, autism and other developmental disorders of higher cognitive functioning. Her publications include numerous papers on autism, epilepsy related language disorders and the Ketogenic Diet. She has shared her work through national and international meetings, and has been a peer reviewer for a variety of medical journals, including <em>Epilepsia</em> and <em>Cephalgia</em>.</p><p>Dr. Ballaban-Gil is board certified by the American Board of Psychiatry and Neurology in Neurology with special competence in Child Neurology and with Certification in Epilepsy.</p>
Howard Geyer
<p>Dr. Howard Geyer is Director, Division of Movement Disorders, Montefiore, and Assistant Professor, Neurology, Albert Einstein College of Medicine. He received his MD and PhD degrees from the University of Pennsylvania. He was chief resident in Neurology at Montefiore, where he also completed a fellowship in Clinical Neurophysiology. He completed an additional fellowship in Movement Disorders at Beth Israel Medical Center. Dr. Geyer regularly lectures and contributes to book chapters and journal articles on a variety of neurologic topics.</p>
Aristea S. Galanopoulou
<p>The maturation of GABA<sub>A</sub><span class="apple-converted-space"> </span>receptor-mediated signaling from depolarizing to inhibitory is an age-related process controlled by cation chloride cotransporters, such as KCC2. As a result, GABA exerts dual functions, being an important neurotrophic factor during early development and the principal inhibitory neurotransmitter of the mature central nervous system. In our laboratory we have been investigating the age mechanisms through which early life stressors and seizures may disrupt the normal patterns of brain development, by disrupting the neurotrophic effects of GABA. We are also studying methods to reverse these adverse processes. Furthermore, we are very interested in understanding how epileptogenesis proceeds in the developing brain and what is the specific role of GABA<sub>A</sub><span class="apple-converted-space"> </span>receptors in this process.</p>
<p>To better understand the pathophysiology and design better methods to treat catastrophic early life epilepsies, we are developing and studying new models of early life epilepsy. These include models of symptomatic infantile spasms that recapitulate most of the features of the human condition. Several projects are under way to (a) elucidate the pathophysiology of infantile spasms, and (b) conduct preclinical trials to find better treatments for spasms and the associated comorbidities. Our studies have provided preclinical evidence for new potential treatments with disease modifying properties for these early life epileptic encephalopathies, such as mTOR inhibitor, carisbamate and a new vigabatrin analog.</p>
<p>Post-traumatic epilepsy is a common consequence of traumatic brain injury leading to high morbidity and morbidity. Our lab is participating in an international multicenter preclinical consortium, EpiBioS4Rx, leading efforts to develop better therapies for post-traumatic epilepsy. We use a rodent model of traumatic brain injury to identify targets and test for better therapies, through a combination of expression studies, in vivo behavioral and electrophysiologic monitoring and therapy screening to identify antiepileptogenic compounds. Furthermore, through a separate project, we are looking into factors predicting epilepsy and behavioral outcomes after traumatic brain injury.</p>
<p>Genetic etiologies are often identified in patients with epilepsies. Our lab has been investigating genes involved in lissencephaly associated epilepsies and developmental disorders as well as Rett syndrome which is due to MeCP2 gene mutations. Through the use of mouse models we have been investigating genotype-phenotype correlations and mechanisms involved with the ultimate goal of testing therapies.</p>
<p>Students interested in these projects will gain exposure to a variety of<span class="apple-converted-space"> </span><em>in vivo</em><span class="apple-converted-space"> </span>and<span class="apple-converted-space"> </span><em>in vitro</em><span class="apple-converted-space"> </span>techniques that combine molecular biology<em>, in vivo</em><span class="apple-converted-space"> </span>and<span class="apple-converted-space"> </span><em>in vitro</em><span class="apple-converted-space"> </span>electrophysiology, histological, and behavioral studies and will be involved in projects with direct translational relevance to the clinical practice, i.e. identification of novel therapies. </p>
<p> </p>
<p><!--EndFragment--></p>
Adult epileptology, clinical neurophysiology
Post-traumatic epilepsy, developmental and epileptic encephalopathies, infantile spasms, GABA receptors, biomarkers, treatments for epilepsies
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS: “Dissociated gender-specific effects of recurrent seizures on GABA signaling in CA1 pyramidal neurons: role of GABA<sub>A </sub>receptors”: J Neurosci 28 (7): 1557-67 (2008). PMID 18272677. https://www.jneurosci.org/content/28/7/1557.long</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Briggs SW, Mowrey W, Hall CB,<strong> </strong>Galanopoulou AS<strong>. </strong>CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. Epilepsia (2014) 55(1):94-102. PMID 24321005. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.12424 </span>…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS and Moshé SL. Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies. Neurobiology of Disease (2015): Neurobiol Dis. 2015 Jul;79:135-49. PMID 25968935. https://www.sciencedirect.com/science/article/pii/S096999611500162X?via…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, Mowrey WB, Liu W, Li Q, Shandra O, Moshe SL. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Preclinical Screening for Treatments for Infantile Spasms in the Multiple Hit Rat Model of Infantile Spasms: An Update. Neurochem Res. 2017;42:1949-61. PMID 28462453. https://link.springer.com/article/10.1007%2Fs11064-017-2282-0</span></p…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, French JA, O’Brien T, Simonato M. “Harmonization in preclinical epilepsy research: a joint AES/ILAE translational initiative”. Epilepsia (2017) 58 (Suppl 4):7-9. PMID 29105072. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13921</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Ono T, Wagenaar J, Giorgi FS et al, Galanopoulou AS. A companion to the preclinical common data elements and case report forms for rodent EEG studies. A report of the TASK3 EEG Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2018;3:90-103. PMID 30450486. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210053/pdf/EPI4-3-90.pdf<…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">7.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Akman O, Raol YH, Auvin S et al, Galanopoulou AS. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Methodologic recommendations and possible interpretations of video-EEG recordings in immature rodents used as experimental controls: A TASK1-WG2 report of the ILAE/AES Joint Translational Task Force. Epilepsia Open. (2018) vol 3: 437-459. PMID 30525114. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276777/pdf/EPI4-3-437.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">8.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Li, Q, Liu W, Moshé SL, Galanopoulou AS. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">“Acquired parvalbumin-selective interneuronopathy in the multiple-hit model of infantile spasms: a putative basis for the partial responsiveness to vigabatrin analogs?” Epilepsia Open (2018) vol 3 (S2): 155-164. PMID 30564774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293059/pdf/EPI4-3-155.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">9.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Salar S, Moshe SL, Galanopoulou AS. Metabolic etiologies in West syndrome. </span><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Epilepsia Open. 2018;3:134-66.</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;"><a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/29881795"><span lang="PT-BR">https://www.ncbi.nlm.nih.gov/pubmed/29881795</span></a></span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">10.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Ali I, Casillas-Espinosa PM et al, Galanopoulou AS. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">In search of antiepileptogenic treatments for post-traumatic epilepsy. Neurobiol Dis. (2019) 123: 86-99 (2019). PMID: 29936231. <a style="color: #954f72; text-decoration: underline;" href="https://www.sciencedirect.com/science/article/pii/S0969996118301980?via…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">11.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler MF, Ballaban-Gil K, Haut SR, Moshe SL, Boro A. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open. 2020;5:314-24.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/32537529">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">12.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Outcome of Hospitalized Parkinson's Disease Patients with and without COVID-19. Mov Disord Clin Pract. 2021;8:859-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34226870">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">13.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Akman O, Briggs SW, Mowrey WB, Moshe SL, Galanopoulou AS. Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions. Epilepsia. 2021;62:1985-99.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34212374">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">14.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Loscher W, Lubbers L, O'Brien TJ, Staley K, Vezzani A, D'Ambrosio R, White HS, Sontheimer H, Wolf JA, Twyman R, Whittemore V, Wilcox KS, Klein B. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open. 2021;6:276-96.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34033232">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">15.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Kubova H, Auvin S, Mantegazza M, Barker-Haliski M, Galanopoulou AS, Reid CA, Semple BD. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">A companion to the preclinical common data elements for rodent models of pediatric acquired epilepsy: A report of the TASK3-WG1B, Pediatric and Genetic Models Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2022.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35950641">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">16.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Medel-Matus JS, Lagishetty V, Santana-Gomez C, Shin D, Mowrey W, Staba RJ, Galanopoulou AS, Sankar R, Jacobs JP, Mazarati AM. Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia. 2022;63:1835-48.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35366338">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">17.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Mowrey WB, Liu W, Li Q, McCullough J, Aniceto R, Lin IH, Eklund M, Casillas-Espinosa PM, Ali I, Santana-Gomez C, Coles L, Shultz SR, Jones N, Staba R, O'Brien TJ, Moshe SL, Agoston DV, Galanopoulou AS, EpiBio SRSG. Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam. Epilepsia Open. 2023;8:586-608.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37026764">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">18.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Coles L, Forcelli PA, Leclercq K, Katsarou AM, Klein BD, Potschka H, Koehling R, Harte-Hargrove L, Galanopoulou AS, Metcalf CS. Preclinical common data elements for general pharmacological studies (pharmacokinetic sample collection, tolerability, and drug administration). A report of the TASK3-WG1A General Pharmacology Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2023.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36896626">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">19.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Guerrini R, Conti V, Mantegazza M, Balestrini S, Galanopoulou AS, Benfenati F. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiol Rev. 2023;103:433-513.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35951482">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">20.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Auvin S, Galanopoulou AS, Moshe SL, Potschka H, Rocha L, Walker MC. Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force. Epilepsia. 2023;64:2891-908. <a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37676719">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">21.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Grandizoli Saletti P, Casillas-Espinosa PM, Panagiotis Lisgaras C, Bi Mowrey W, Li Q, Liu W, Brady RD, Ali I, Silva J, Yamakawa G, Hudson M, Li C, Braine EL, Coles L, Cloyd JC, Jones NC, Shultz SR, Moshe SL, O'Brien TJ, Galanopoulou AS. Tau Phosphorylation Patterns in the Rat Cerebral Cortex After Traumatic Brain Injury and Sodium Selenate Effects: An Epibios4rx Project 2 Study. J Neurotrauma. 2024;41:222-43.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36950806">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">22.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Lucasius C, Grigorovsky V, Nariai H, Galanopoulou AS, Gursky J, Moshe SL, Bardakjian BL. Biomimetic Deep Learning Networks With Applications to Epileptic Spasms and Seizure Prediction. IEEE Trans Biomed Eng. 2024;71:1056-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37851549">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">23.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Samfira IMA, Galanopoulou AS, Nariai H, Gursky JM, Moshe SL, Bardakjian BL. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">EEG-based spatiotemporal dynamics of fast ripple networks and hubs in infantile epileptic spasms. Epilepsia Open. 2024;9:122-37.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37743321">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">24.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Perucca E, French JA, Aljandeel G, Balestrini S, Braga P, Burneo JG, Felli AC, Cross JH, Galanopoulou AS, Jain S, Jiang Y, Kalviainen R, Lim SH, Meador KJ, Mogal Z, Nabbout R, Sofia F, Somerville E, Sperling MR, Triki C, Trinka E, Walker MC, Wiebe S, Wilmshurst JM, Wirrell E, Yacubian EM, Kapur J. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65:533-41.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38279786">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">25.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Pease M, Gupta K, Moshe SL, Correa DJ, Galanopoulou AS, Okonkwo DO, Gonzalez-Martinez J, Shutter L, Diaz-Arrastia R, Castellano JF. </span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Insights into epileptogenesis from post-traumatic epilepsy. Nat Rev Neurol. 2024;20:298-312. <a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38570704">https://www.ncbi.nlm.nih…;
<p></p>
<p class="MsoNormal" style="font-size: medium;"><span style="font-size: 9pt; font-family: Verdana, sans-serif;"> </span></p>
Victor Ferastraoaru
Nicole Feirsen
<p>Nicole Feirsen, Ph.D. is a licensed clinical psychologist who specializes in neuropsychological assessments of individuals across the lifespan. She evaluates cognitive and emotional functioning in individuals with a variety of neurological, medical, and psychiatric disorders, including dementia, stroke, cancers, autoimmune diseases, epilepsy, traumatic brain injury, mood disorders, and attention disorders. Her current research is focused on the development and validation of a screening measure designed to efficiently identify cognitive impairment in a wide variety of patient populations. She earned her doctorate in clinical neuropsychology at the Graduate Center of the City University of New York and then completed her internship in clinical neuropsychology at Northwell Health. She also completed a postdoctoral fellowship in clinical neuropsychology at Montefiore Medical Center. </p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;">Freilich, B. M., <strong>Feirsen, N.</strong>, Welton, E. I., Mowrey, W. B., & Rubinstein, T. B. (2019). Validation of the Attention, Memory, and Frontal Abilities Screening Test (AMFAST). <em>Assessment</em>. </span><a href="https://doi.org/10.1177/1073191118822734"><span style="color: #0000ff; font-family: Calibri; font-size: medium;">https://doi.org/10.1177/1073191118822734</span></a></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;">Chacko, A., Bedard, A., Marks, D., Gopalan, G., <strong>Feirsen, N</strong>., Uderman, J., Chimiklis, A.,Rajwan, E., Cornwell, M., Anderson, L., Zwilling, A. & Ramon, M. (2018). Sequenced neurocognitive and behavioral parent training for the treatment of ADHD in school-age children. <em>Child Neuropsychology</em>, 24(4), 427-450. doi: 10.1080/09297049.2017.1282450 </span></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;"> Chacko, A., Wymbs, B. T., Rajwan, E., Wymbs, F., & <strong>Feirsen, N.</strong> (2017). Characteristics of parents of children with ADHD who never attend, drop out, and complete behavioral parent training. <em>Journal of Child and Family Studies</em>, 26(3), 950-960. doi:10.1007/s10826-016-0618-z</span></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;"> Chacko, A.,Bedard, A., Marks, D., <strong>Feirsen, N</strong>., Uderman, J., Chimiklis, A., Rajwan, E., Cornwell, M., Anderson, L., Zwilling, A. & Ramon, M. (2014). A randomized clinical trial of Cogmed Working Memory Training in school-age children with ADHD: A replication in a diverse sample using a control condition. <em>Journal of Child Psychology and Psychiatry</em>, 55(3), 247-55. doi: 10.1111/jcpp.12146</span></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;"> Chacko, A., Uderman, J., <strong>Feirsen, N</strong>., Bedard, AC, & Marks, D. (2013). Learning and Cognitive Disorders: Multidiscipline Treatment Approaches. <em>Child and Adolescent Psychiatric Clinics of North America</em>, 22(3), 457-477.</span></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;"> Chacko, A., <strong>Feirsen, N.</strong>, Bedard, A.C., Marks, D., Uderman, J., & Chimiklis, A. (2013). Cogmed Working Memory Training for Youth with ADHD: A Closer Examination of Efficacy Utilizing Evidence Based Criteria. <em>Journal of Clinical Child & Adolescent Psychology</em>, 0(0), 1-15. </span></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;">Anagnostou, E., Chaplin, W., Watner, D., Silverman, J., Smith, C., Zagursky, K., Kryzak, L., Corwin, T., <strong>Feirsen, N</strong>., Tanel, N., & Hollander, E. (2011). Factor analysis of repetitive behaviors in autism as measured by the Y-BOCS. <em>Journal of Neuropsychiatry and Clinical Neuroscience</em>, 23(3), 332-339. </span></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;">Chacko, A., Newcorn, J., <strong>Feirsen, N</strong>., & Uderman, J. (2010). Improving medication adherence in pediatric health conditions: A focus on ADHD in youth. <em>Current Pharmaceutical Design</em>. 2416 – 2423.</span></p>
<p> </p>
<p><span style="font-family: Calibri; font-size: medium;">Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., <strong>Feirsen, N</strong>., Pepa, L., & Anagnostou, L. (2009). Divalproex Sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. <em>Neuropharmacology</em>. 1-9.</span></p>
Sameen Farooq
<p>Dr. Farooq is board certified in Internal Medicine, Addiction Medicine, Palliative and Hospice Medicine and Obesity Medicine. He works as a direct care Internal Medicine hospitalist at Moses campus.</p>